- Home
- CPTN vs LVTX Comparison
CPTN vs LVTX Comparison
Compare CPTN & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPTN
- LVTX
- Stock Information
- Founded
- CPTN 2016
- LVTX 2016
- Country
- CPTN United States
- LVTX Netherlands
- Employees
- CPTN N/A
- LVTX N/A
- Industry
- CPTN Industrial Machinery/Components
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CPTN Industrials
- LVTX Health Care
- Exchange
- CPTN Nasdaq
- LVTX Nasdaq
- Market Cap
- CPTN 50.5M
- LVTX 43.7M
- IPO Year
- CPTN N/A
- LVTX 2021
- Fundamental
- Price
- CPTN $3.12
- LVTX $1.57
- Analyst Decision
- CPTN Hold
- LVTX Strong Buy
- Analyst Count
- CPTN 2
- LVTX 2
- Target Price
- CPTN $2.50
- LVTX $6.00
- AVG Volume (30 Days)
- CPTN 11.2K
- LVTX 71.0K
- Earning Date
- CPTN 11-07-2024
- LVTX 11-22-2024
- Dividend Yield
- CPTN N/A
- LVTX N/A
- EPS Growth
- CPTN N/A
- LVTX N/A
- EPS
- CPTN N/A
- LVTX N/A
- Revenue
- CPTN $17,872,000.00
- LVTX $7,398,000.00
- Revenue This Year
- CPTN $50.39
- LVTX N/A
- Revenue Next Year
- CPTN $48.05
- LVTX N/A
- P/E Ratio
- CPTN N/A
- LVTX N/A
- Revenue Growth
- CPTN 84.59
- LVTX N/A
- 52 Week Low
- CPTN $2.38
- LVTX $1.35
- 52 Week High
- CPTN $5.20
- LVTX $6.47
- Technical
- Relative Strength Index (RSI)
- CPTN 45.65
- LVTX 37.66
- Support Level
- CPTN $3.10
- LVTX $1.75
- Resistance Level
- CPTN $3.16
- LVTX $1.86
- Average True Range (ATR)
- CPTN 0.03
- LVTX 0.13
- MACD
- CPTN -0.00
- LVTX -0.04
- Stochastic Oscillator
- CPTN 33.33
- LVTX 4.35
About CPTN Cepton Inc.
Cepton Inc provides lidar-based solutions for a range of markets such as automotive, smart cities, smart spaces and smart industrial applications. The company's patented MMT-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.